We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and ...

Cantor Fitzgerald reiterated their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $21.

Amicus Therapeutics, Inc. (FOLD) stock saw a modest uptick, ending the day at $9.41 which represents a slight increase of $0.05 or 0.53% from the prior close of $9.36. The stock opened at $9.46 and ...

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” ...

Analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report) and keeping the price target at $20.00.Stay Ahead ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on FOLD stock, giving a Buy rating on January 13.Stay Ahead of ...

PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines ...

Amicus Therapeutics reports 2024 revenue of $528M, a 32% increase, with positive 2025 growth projections for key therapies. 2024 total revenue reached $528.5 million, marking a significant year ...

On Tuesday, Goldman Sachs reiterated its Neutral rating for Amicus Therapeutics (NASDAQ:FOLD) shares, maintaining a $14.00 price target. According to InvestingPro data, analyst targets for the ...